Benefits
GLP-1 secretion enhancement (3.5-fold AUC)
In a crossover trial of 36 overweight adults, Trpti at 300 mg/day produced a clear dose-dependent enhancement of GLP-1 secretion — approximately 3.5-fold greater area-under-the-curve (AUC) and 1.7-fold higher Cmax vs placebo. GLP-1 is the same hormone targeted by semaglutide and other GLP-1 receptor agonist drugs. Effect emerged within 30 minutes and sustained after both breakfast and lunch.
Akkermansia muciniphila enrichment
In a 12-week trial of 57 adults with obesity (BMI 30-40 kg/m²), Trpti at 300 mg/day selectively enriched Akkermansia muciniphila — a beneficial gut bacterium linked to gut barrier function, metabolic health, and reduced inflammation. Akkermansia abundance is consistently reduced in obesity and metabolic syndrome; Trpti's enrichment effect addresses this dysbiosis.
Faecalibacterium prausnitzii enrichment
Same 12-week trial also documented enrichment of Faecalibacterium prausnitzii — another beneficial gut bacterium associated with anti-inflammatory effects and gut barrier integrity. The dual enrichment of these two key beneficial species is unusual for a non-prebiotic, non-probiotic supplement — Trpti achieves this via OEA's direct gut signaling effects.
Intestinal barrier function improvement
Trpti supplementation improved intestinal barrier function biomarkers in the 12-week obesity trial — relevant for the 'leaky gut' framework where compromised intestinal permeability contributes to systemic inflammation. Combined with the microbiome effects, supports overall gut-axis health rather than just narrow satiety signaling.
Immune modulation (IL-2 up, IL-1β down)
The 12-week trial documented immune modulation effects — increased IL-2 (a regulatory cytokine) and decreased IL-1β (a pro-inflammatory cytokine). The pattern indicates enhanced immune regulation rather than blanket immunosuppression or stimulation. Connects gut health to systemic immune balance via the gut-immune axis.
Modest weight loss (BMI <35 subgroup)
Trpti supplementation promoted modest weight loss in the 12-week trial, particularly in individuals with BMI below 35. Effect is smaller than pharmaceutical GLP-1 agonists like semaglutide but comes without the GI side effects (severe nausea, vomiting, constipation) that limit GLP-1 drug tolerability for many patients.
PPAR-α activation mechanism
OEA's physiological actions stem largely from high-affinity binding to PPAR-α (peroxisome proliferator-activated receptor-alpha), a nuclear receptor that promotes lipolysis, fatty acid oxidation, and satiety. PPAR-α activation in the small intestine signals satiety to the brain via vagal afferents — explaining OEA's well-documented appetite-suppressing effects.
Natural alternative to synthetic GLP-1 agonists
Trpti is positioned as a natural support for the body's own GLP-1 production rather than direct GLP-1 receptor agonism — distinguishing it from semaglutide-class drugs. The natural mechanism avoids the severe nausea, vomiting, and GI side effects common with synthetic agonists. Quality-of-life, stress, and sleep scores remained stable across the 12-week trial, indicating no compromise on these dimensions.
Mechanism of action
PPAR-α nuclear receptor binding
OEA binds with high affinity to peroxisome proliferator-activated receptor-alpha (PPAR-α) — a nuclear receptor that regulates lipid metabolism, satiety, and energy homeostasis. PPAR-α activation increases fatty acid oxidation in liver and muscle, promotes lipolysis in adipose tissue, and signals satiety to the brain via vagal afferents from the small intestine.
Intestinal L-cell GLP-1 secretion
OEA stimulates GLP-1 release from intestinal L-cells — the same hormone targeted by pharmaceutical GLP-1 receptor agonists. The natural mechanism enhances the body's own production rather than directly activating GLP-1 receptors, theoretically providing a more physiological response pattern without the supraphysiological GLP-1 levels of injectable medications.
Vagal afferent satiety signaling
OEA activates vagal afferent neurons in the small intestine that project to the nucleus tractus solitarius (NTS) and hypothalamic satiety centers. This gut-brain signaling pathway is a key driver of post-meal satiety and reduced subsequent food intake — independent of GLP-1 effects.
LipiSperse® bioavailability enhancement
LipiSperse® is a cold-water-dispersible delivery technology by Pharmako Biotechnologies (Australia). The technology shepherds OEA through the GI tract and delivers it efficiently to the intestines where it best enhances GLP-1 production. Addresses OEA's poor native solubility and bioavailability — making oral OEA supplementation practically effective at sub-gram doses.
Direct gut microbiome modulation
OEA's effects on Akkermansia muciniphila and Faecalibacterium prausnitzii enrichment occur without the supplement itself being a prebiotic or probiotic. Mechanism may involve OEA's effects on intestinal mucus production, gut motility, and microenvironmental conditions that favor these beneficial species. Bidirectional: a good microbiome also helps endogenous OEA production.
Endocannabinoid-like signaling
OEA is an N-acyl ethanolamide structurally related to anandamide and PEA (palmitoylethanolamide). Unlike anandamide, OEA does not activate CB1 or CB2 cannabinoid receptors — it works primarily via PPAR-α and TRPV1. The structural relationship places OEA in a broader family of endogenous bioactive lipids with metabolic and inflammatory regulatory roles.
Clinical trials
Randomized double-blind placebo-controlled trial of Trpti at 300 mg/day (delivering 250 mg OEA) vs placebo for 12 weeks. Published in Gut Microbes Reports 2026;3(1) (doi: 10.1080/29933935.2026.2622259). Authors: Batacan R et al. Outcomes: shotgun metagenomics, microbiome profiling, intestinal barrier biomarkers, inflammatory markers.
57 adults with obesity (BMI 30-40 kg/m²), age 18-65. 12-week intervention.
Selective enrichment of Akkermansia muciniphila and Faecalibacterium prausnitzii — both linked to gut barrier function and metabolic health. Improved intestinal barrier function biomarkers and inflammatory signaling (IL-2 up, IL-1β down). Modest weight loss, particularly in BMI <35 subgroup. Overall microbial diversity remained stable. OEA was safe and well-tolerated with no adverse changes in clinical biomarkers.
Randomized double-blind placebo-controlled crossover trial of Trpti at 150 mg and 300 mg doses vs placebo in overweight but otherwise healthy adults. Primary endpoint: GLP-1 secretion measured over 8 hours after standardized breakfast and lunch test meals.
36 overweight adults. Crossover protocol with multiple dose arms.
300 mg Trpti produced a clear dose-dependent enhancement of GLP-1 secretion vs placebo — rapid rise within 30 minutes and sustained elevations after both breakfast and lunch. Approximately 3.5-fold greater AUC and 1.7-fold higher Cmax compared to placebo. The 150 mg dose suppressed GLP-1 below baseline; placebo induced only minor increases. Established 300 mg/day as the effective clinical dose.
Ongoing clinical trial evaluating whether Trpti can reduce plasma imidazole propionate levels (a gut microbiota-derived metabolite linked to insulin resistance) and improve insulin sensitivity in healthy adults. Three-arm parallel design comparing Trpti 150 mg, Trpti 300 mg, and placebo over 28 days. Registered on ClinicalTrials.veeva.com.
Healthy adults aged 18+ with BMI 18.5-29.9 kg/m². 28-day intervention.
Ongoing — results expected to expand the metabolic health evidence base beyond the pivotal 12-week obesity trial. Specifically targets the imidazole propionate-insulin sensitivity axis, a newly appreciated pathway connecting gut microbiome composition to insulin resistance. Will further characterize the dose-response relationship established in earlier trials.